Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Asset Writedowns and Impairment (2020 - 2024)

Historic Asset Writedowns and Impairment for Arcadia Biosciences (RKDA) over the last 5 years, with Q3 2024 value amounting to $154000.0.

  • Arcadia Biosciences' Asset Writedowns and Impairment fell 3888.89% to $154000.0 in Q3 2024 from the same period last year, while for Sep 2025 it was $154000.0, marking a year-over-year change of 0.0%. This contributed to the annual value of $154000.0 for FY2024, which is 6531.53% down from last year.
  • Per Arcadia Biosciences' latest filing, its Asset Writedowns and Impairment stood at $154000.0 for Q3 2024, which was down 3888.89% from $252000.0 recorded in Q3 2023.
  • In the past 5 years, Arcadia Biosciences' Asset Writedowns and Impairment ranged from a high of $1.8 million in Q4 2021 and a low of $15000.0 during Q3 2022
  • In the last 5 years, Arcadia Biosciences' Asset Writedowns and Impairment had a median value of $593000.0 in 2021 and averaged $678687.5.
  • Its Asset Writedowns and Impairment has fluctuated over the past 5 years, first tumbled by 9816.63% in 2022, then soared by 158000.0% in 2023.
  • Over the past 5 years, Arcadia Biosciences' Asset Writedowns and Impairment (Quarter) stood at $1.2 million in 2020, then soared by 49.83% to $1.8 million in 2021, then crashed by 46.05% to $970000.0 in 2022, then plummeted by 74.02% to $252000.0 in 2023, then crashed by 38.89% to $154000.0 in 2024.
  • Its Asset Writedowns and Impairment stands at $154000.0 for Q3 2024, versus $252000.0 for Q3 2023 and $169000.0 for Q2 2023.